KRTX (karunatx.com) יחס שווי שוק לשווי בספרים

Did the triumphant multi-billion dollar acquisition of the brand confirm the scientific value of Karuna Therapeutics (KRTX)? The answer lies in the monopoly status of the drug KarXT, which is protected by strict FDA patents. Simultaneously, the company is implementing closed-loop water cycles for environmental sustainability. This market-to-book value chart confirms this optimism, where the parameter mark equals 10.02.

The indicator is calculated as the quotient of the current market value of all shares divided by the book value of net assets. This metric determines the extent to which the market overvalues the business relative to its tangible asset base. For Karuna Therapeutics (KRTX), which currently has no revenue, the value reflects investor expectations for future drug sales. Analyzing the historical price-to-book ratio allows for an assessment of the speculative premium applied to the biotech company's capital.